BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › HER2-enriched tumor initiating cell (HTIC) genomic predictor of response following neoadjuvant trastuzumab-based chemotherapy in HER2+...

Dataset: HER2-enriched tumor initiating cell (HTIC) genomic predictor of response following neoadjuvant trastuzumab-based chemotherapy in HER2+ breast cancer

We identified a 17-gene Her2-enriched tumor initiating cell (HTIC) signature in MMTV-Her2/Neu mouse mammary TICs. Here, we show that...

Registered by ArrayExpress Uploader
View Dataset

We identified a 17-gene Her2-enriched tumor initiating cell (HTIC) signature in MMTV-Her2/Neu mouse mammary TICs. Here, we show that patients with HTICS+ HER2+:ERα− tumors are more likely to achieve a pathologic complete response to trastuzumab-based neoadjuvant chemotherapy compared with HER2+:ER+ tumors. Neoadjuvant study of 50 HER2-positive breast cancer cases treated with trastuzumab-based chemotherapy pre-operatively. Pre-treatment FNA from primary tumors were obtained and RNA extracted and hybridized to Affymetrix microarrays according to manufacturer protocol. Pathologic response was assessed at the end of neoadjuvant treatment.

Species:
human

Samples:
50

Source:
E-GEOD-37946

Updated:
Dec.12, 2014

Registered:
Jun.18, 2014


Factors: (via ArrayExpress)
Sample PR AGE ER RESPONSE STAGE
GSM930574 NEG 49 NEG RD IV
GSM930573 POS 62 POS RD IIIC
GSM930572 POS 24 POS RD IIIC
GSM93057 NEG 54 NEG RD IIIC
GSM930570 POS 72 POS RD IIB
GSM930569 NEG 55 NEG RD IIIC
GSM930568 NEG 61 NEG RD IIIC
GSM930567 POS 48 POS RD IIIA
GSM930566 NEG 39 NEG RD IIIC
GSM930565 NEG 50 POS RD IIIA
GSM930564 NEG 44 NEG RD IIA
GSM930563 NEG 51 NEG RD IIB
GSM930562 NEG 61 POS RD IIB
GSM93056 NEG 30 NEG RD IIIB
GSM930560 NEG 52 NEG RD IIIA
GSM930559 NEG 69 NEG RD IIA
GSM930558 NEG 56 POS RD IIIC
GSM930557 NEG 73 NEG RD IIA
GSM930556 POS 47 POS RD IIIC
GSM930555 NEG 41 NEG RD IIIC
GSM930554 POS 49 POS RD IIA
GSM930553 POS 28 POS RD IIIB
GSM930552 NEG 57 NEG RD IIA
GSM93055 NEG 46 NEG PCR IIIC
GSM930550 POS 30 POS PCR not specified
GSM930549 NEG 65 NEG PCR IIB
GSM930548 POS 52 POS PCR IIIB
GSM930547 NEG 56 NEG PCR IIB
GSM93055 NEG 46 NEG PCR IIIC
GSM930545 POS 56 POS PCR IIIA
GSM930544 NEG 53 NEG PCR IIB
GSM930543 NEG 62 NEG PCR IIIC
GSM930542 NEG 55 NEG PCR IIA
GSM93054 NEG 51 NEG PCR IIIB
GSM930540 POS 53 POS PCR IIIA
GSM930539 NEG 41 NEG PCR IIIC
GSM930538 NEG 50 POS PCR IIIA
GSM930537 NEG 63 POS PCR IIA
GSM930536 NEG 38 POS PCR I
GSM930535 NEG 43 NEG PCR IIIA
GSM930534 NEG 51 NEG PCR IIIC
GSM930533 NEG 45 NEG PCR IIIC
GSM930532 POS 56 NEG PCR IIIA
GSM93053 NEG 47 NEG PCR IIA
GSM930530 NEG 36 NEG PCR I
GSM930529 POS 38 POS PCR IIA
GSM930528 NEG 30 NEG PCR IIIA
GSM930527 NEG 52 NEG PCR IIIB
GSM930526 NEG 34 NEG PCR IIA
GSM930525 NEG 50 NEG PCR IIA

Tags

  • breast
  • breast cancer
  • cancer
  • cell

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2025 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use